clinical trial · NCT04243499
First-in-Human Study of ICT01 in Patients With Advanced Cancer
Solid Tumor, AdultHematopoietic/Lymphoid CancerIV ICT01
brief summary
Part 1 will be a dose escalation study of IV ICT01 (a monoclonal antibody targeting BTN3A) as monotherapy in patients with advanced solid or hematologic tumors, followed by a cohort examining the combination of ICT01 plus pembrolizumab (Keytruda). Part 2 will be a cohort expansion into 2 solid tumor indications and one hematologic malignancy for ICT01 monotherapy, and 3 solid tumor indications for the combination of ICT01 plus pembrolizumab.
started
Mar 5, 2020
primary completion
Oct 15, 2025
completion
Oct 1, 2026
last updated
Jan 27, 2026
official title
A First-in-human, Two-part Clinical Study to Assess the Safety, Tolerability and Activity of IV Doses of ICT01 as Monotherapy and in Combination With a Checkpoint Inhibitor, in Patients With Advanced-stage, Relapsed/Refractory Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol